20-Mar-2026
Major Investor Makes Bold Move Into Neuronetics Stock
TipRanks (Fri, 20-Mar 10:02 PM ET)
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks (Thu, 19-Mar 6:51 AM ET)
Major Investor Quietly Ramps Up Stake in Neuronetics
TipRanks (Wed, 18-Mar 10:04 PM ET)
Neuronetics Earnings Call: Growth Momentum Meets Margin Strain
TipRanks (Tue, 17-Mar 8:08 PM ET)
Seeking Alpha News (Tue, 17-Mar 1:13 PM ET)
Neuronetics Appoints New CEO to Lead Next Growth Phase
TipRanks (Tue, 17-Mar 8:42 AM ET)
Neuronetics GAAP EPS of -$0.10 beats by $0.01, revenue of $41.78M beats by $0.94M
Seeking Alpha News (Tue, 17-Mar 7:53 AM ET)
Neuronetics appoints Dan Reuvers as chief executive officer
Seeking Alpha News (Tue, 17-Mar 7:50 AM ET)
Neuronetics Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Globe Newswire (Tue, 17-Mar 7:50 AM ET)
Neuronetics Appoints Dan Reuvers as President and Chief Executive Officer
Globe Newswire (Tue, 17-Mar 7:45 AM ET)
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.
Neuronetics trades on the NASDAQ stock market under the symbol STIM.
As of March 20, 2026, STIM stock price declined to $1.45 with 1,858,756 million shares trading.
STIM has a beta of 1.51, meaning it tends to be more sensitive to market movements. STIM has a correlation of 0.08 to the broad based SPY ETF.
STIM has a market cap of $95.87 million. This is considered a Micro Cap stock.
Last quarter Neuronetics reported $42 million in Revenue and -$.10 earnings per share. This beat revenue expectation by $933,500 and exceeded earnings estimates by $.01.
In the last 3 years, STIM traded as high as $5.92 and as low as $.52.
The top ETF exchange traded funds that STIM belongs to (by Net Assets): VTI, IWM, PSIL, VXF, IWO.
STIM has underperformed the market in the last year with a return of -70.6%, while SPY returned +16.6%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in STIM shares. However, STIM has outperformed the market in the last 3 month and 2 week periods, returning +3.6% and +5.1%, while SPY returned -4.4% and -3.3%, respectively. This indicates STIM has been having a stronger performance recently.
STIM support price is $1.41 and resistance is $1.62 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that STIM shares will trade within this expected range on the day.